Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 4Sarcoma 2

Conditions

Melanoma 31Carcinoma, Renal Cell 19Carcinoma, Non-Small-Cell Lung 19Neoplasm Metastasis 11Carcinoma, Hepatocellular 9Brain Neoplasms 8Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Pancreatic Neoplasms 5Lung Neoplasms 5Clear-cell metastatic renal cell carcinoma 5Carcinoma, Transitional Cell 5Uveal Melanoma 4Skin Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Multiple Myeloma 4Mesothelioma 4Kidney Neoplasms 4Glioblastoma 4Carcinoma, Basal Cell 4Carcinoma 4Sarcoma 3Recurrence 3Myelodysplastic Syndromes 3Liver Neoplasms 3Leukemia, Myeloid, Acute 3Gliosarcoma 3Colorectal Neoplasms 3Breast Neoplasms 3

Interventions

Temozolomide 40Magnetic Resonance Spectroscopy 19Radiotherapy 18Specimen Handling 14Radiation 12Bevacizumab 11Lomustine 9pembrolizumab 6fludarabine 5Surgical Procedures, Operative 5atezolizumab 4Nivolumab 4Ipilimumab 4Cyclophosphamide 4Carboplatin 4Biopsy 4cemiplimab 3azeliragon 3Immunoglobulin G 3Disulfides 3Aminolevulinic Acid 3veliparib 2trametinib 2rocakinogene sifuplasmid 2poly ICLC 2olaparib 2lutetium Lu 177 dotatate 2durvalumab 2dabrafenib 2contrast agent BR1 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Glioblastoma × Ipilimumab × 90 days × Clear all
NCT04145115 2026-05-29

A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden

National Cancer Institute (NCI)

Phase 2 Active not recruiting
37 enrolled
CNS

Astrocytoma, Glioblastoma

NCT04003649 2026-05-14

IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

City of Hope Medical Center

Phase 1 Active not recruiting
20 enrolled
CNS

Glioblastoma

NCT04817254 2026-04-17

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
47 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT07134842 2026-04-09

WinGlio-ipi

University College, London

Phase 1 Recruiting
16 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡